Main Industry
Biotechnology
Main Product/Service
Acepodia’s core offering is allogeneic cell‑therapy for cancer — using targeted design and cell‑engineering technologies to develop safe and effective therapeutic cell drugs, aiming to provide patients with a next‑generation, broadly applicable cancer tre
Founded Year
2023
Unified Business No.
82983710
Status
Active
Number of Employees
60
Total Paid-in
Capital
0 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2023)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Acepodia Inc., a member (No. 64) of the Taiwan Research‑based Biopharmaceutical Manufacturers Association (TRPMA), is a biotech startup focused on developing novel allogeneic cell therapies for cancer, aiming to advance new possibilities in oncology treatment.
